The fast-growing number of patients with neuropsychiatric disorders results in an enormous individual, social, and economic burden of disease.
Globally, 615 million people, or almost 10% of the global population, are currently living with a mental health condition.
Of those, more than 50% (320 million people) suffer from Major Depressive Disorder (MDD).
Out of those, 30% (approximately 100 million patients) are suffering from Treatment-Resistant Depression (TRD) – referring to patients who have not responded to at least two approved antidepressant treatments within the same depressive episode – which has even greater economic and societal cost than non-TRD depression.
Despite the widespread and growing use of antidepressant therapies, most patients do not achieve the desired outcome.
72% of patients fail to achieve remission after the first line of treatment, and 34% fail to remit even after multiple lines meeting the criteria for TRD. In addition, 30% of patients do not recover after 24 months, developing a chronic form of depression.
As a result, there is a high need for treatments that work better, cause fewer side effects, act faster and fit into patients’ lives. Meeting patients where they are, with targeted, effective and accessible therapies, can improve the lives of a fast-growing number of patients and relieve health care systems.